Galderma was founded in 1981 as a joint venture between Nestlé and L’Oréal with the goal of establishing a pharmaceutical company exclusively focused on the field of dermatology. Today the company has nearly 4000 employees in 31 affiliates around the world with four manufacturing sites and the largest R&D facility dedicated exclusively to dermatology. Galderma’s important investments in research and development, extensive product portfolio, global presence and expertise in three key segments (prescription drugs, over-the-counter drugs and aesthetic and corrective solutions) have positioned the company as a leader in dermatology.
Prescription Products
|
Prescription dermatology represents the core of Galderma’s business. Galderma is seeking innovative new compounds to develop first-in-class or best-in-class products that provide therapeutic solutions to a wide variety of dermatological conditions.
Disease targets include:
- Acne,
- Psoriasis and steroid-responsive dermatoses,
- Rosacea,
- Onychomycosis,
- Pigmentary disorders,
- Skin cancer,
- Medical solutions for skin senescence.
Our criteria for prescription dermatology development programs include:
- Topical or systemic,
- Small molecule or biological,
- Safety profiled,
- Known mechanism of action,
- Comparative in vitro and in vivo pharmacology data versus reference products,
- Proof of concept in humans.
We are also seeking to acquire or in-license programs or technologies to support and complement our internal research efforts, such as:
- Compound libraries,
- Compound library management (purity, concentration, storage, composition, biased libraries),
- Pathology-oriented cellular assays and in vivo models,
- Validated targets (e.g. GCPR’s, ION channels, enzymes, nuclear receptors).
|
Aesthetic & Corrective Solutions
|
To provide innovative medical solutions that meet the needs of dermatology patients and physicians, Galderma evolved its traditional pharmaceutical business model several years ago to incorporate the aesthetic & corrective market. In 2001, the Company entered into the emerging field of photodynamic therapy, an initiative that progressively accelerated with increased activity and investment. In 2008, Galderma began promoting and selling a botulinum toxin product in Latin America. This activity grew further with the approval and launch of the product in Europe in 2009. Through active partnerships, the Company also expanded its offering to include a range of hyaluronic acid-based dermal fillers and a topical anesthetic product. In 2011, Galderma acquired Q-Med, a Swedish medical device company and leader in the aesthetic market .
Beyond skin senescence, Galderma is also focused on developing medical solutions for corrective and aesthetic applications in most of the other therapeutic areas that the Company serves, including acne, rosacea, psoriasis and steroid-responsive dermatoses, pigmentary disorders, onychomycosis and skin cancer, that help healthcare providers optimize patient outcomes.
|